Copy to clipboard 
Johnson & Johnson MedTech reported 4Q24 orthopedic sales of $2.3 billion, up 2.1% compared to the fourth quarter of 2023. For the full year, the company generated $9.1 billion in orthopedic sales, up 2.4% compared to the prior year.
The company’s two-year restructuring of its orthopedic business and ongoing volume-based procurement headwinds in China limited its growth potential in 2024. However, healthy procedure demand and an evolving technology portfolio generated some positive momentum.
“We’re proud of the continuous improvements in Ortho,” said Johnson & Johnson CFO Joe Wolk. “This is a business that historically was a laggard for MedTech, but tremendous improvements especially with the mid-single-digit growth in hips and knees and continued innovation with our enabling technologies and specifically in VELYS.”
Over the last decade, minimal growth in knee replacement and substantial losses in spine offset the company’s slow but steady growth in hip replacement and trauma. The orthopedic market’s recovery since 2021 helped the company post more competitive growth rates in joint replacement, but trauma and spine remain well below market average.
The company did not provide 2025 guidance for its orthopedic business, but we expect dynamics similar to 2024. Growth is likely to be weighted toward the second half of the year due to tougher first-half competitors.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $941.8 | $903.0 | $38.8 | 4.3% |
| Knees | $398.4 | $386.6 | $11.8 | 3.1% |
| Hips | $418.5 | $397.8 | $20.7 | 5.2% |
| Extremities | $125.0 | $118.6 | $6.3 | 5.3% |
| Spine | $211.5 | $213.6 | ($2.1) | (1%) |
| Trauma | $679.9 | $660.4 | $19.5 | 3% |
| Sports Medicine | $183.8 | $178.0 | $5.8 | 3.3% |
| Orthobiologics | $99.2 | $96.4 | $2.8 | 2.9% |
| Enabling Technology | $19.8 | $18.5 | $1.3 | 7.1% |
| Other | $179.8 | $198.0 | ($18.2) | (9.2%) |
| Total | $2,315.8 | $2,267.9 | $48.0 | 2.1% |
| Segment | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $3,677.6 | $3,487.6 | $190.0 | 5.4% |
| Knees | $1,544.9 | $1,456.0 | $89.0 | 6.1% |
| Hips | $1,638.7 | $1,560.2 | $78.5 | 5% |
| Extremities | $494.0 | $471.5 | $22.6 | 4.8% |
| Spine | $934.1 | $944.0 | ($9.9) | (1%) |
| Trauma | $2,713.1 | $2,651.2 | $61.9 | 2.3% |
| Sports Medicine | $726.1 | $707.2 | $19.0 | 2.7% |
| Orthobiologics | $350.1 | $346.1 | $4.0 | 1.2% |
| Enabling Technology | $71.1 | $66.2 | $4.9 | 7.5% |
| Other | $685.8 | $739.4 | ($53.5) | (7.2%) |
| Total | $9,158.0 | $8,941.6 | $216.4 | 2.4% |
Orthopedic Sales by Geography
| Region | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,459.9 | $1,425.4 | $34.5 | 2.4% |
| OUS | $855.9 | $842.5 | $13.4 | 1.6% |
| EMEA | $392.0 | $383.3 | $8.7 | 2.3% |
| APAC | $280.7 | $278.0 | $2.7 | 1% |
| ROW | $183.2 | $181.1 | $2.0 | 1.1% |
| Total | $2,315.8 | $2,267.9 | $48.0 | 2.1% |
| Region | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $5,689.8 | $5,525.6 | $164.1 | 3% |
| OUS | $3,468.3 | $3,416.0 | $52.3 | 1.5% |
| EMEA | $1,635.1 | $1,582.1 | $53.0 | 3.3% |
| APAC | $1,140.2 | $1,151.7 | ($11.5) | (1%) |
| ROW | $693.0 | $682.2 | $10.8 | 1.6% |
| Total | $9,158.0 | $8,941.6 | $216.4 | 2.4% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $22,520.0 | |
| Cost of Sales | $7,128.0 | 31.7% |
| Selling and Admin | $6,453.0 | 28.7% |
| R & D | $5,298.0 | 23.5% |
| Other | $210.0 | 0.9% |
| Net Earnings | $3,431.0 | 15.2% |
Johnson & Johnson MedTech reported 4Q24 orthopedic sales of $2.3 billion, up 2.1% compared to the fourth quarter of 2023. For the full year, the company generated $9.1 billion in orthopedic sales, up 2.4% compared to the prior year.
The company's two-year restructuring of its orthopedic business and ongoing volume-based procurement...
Johnson & Johnson MedTech reported 4Q24 orthopedic sales of $2.3 billion, up 2.1% compared to the fourth quarter of 2023. For the full year, the company generated $9.1 billion in orthopedic sales, up 2.4% compared to the prior year.
The company’s two-year restructuring of its orthopedic business and ongoing volume-based procurement headwinds in China limited its growth potential in 2024. However, healthy procedure demand and an evolving technology portfolio generated some positive momentum.
“We’re proud of the continuous improvements in Ortho,” said Johnson & Johnson CFO Joe Wolk. “This is a business that historically was a laggard for MedTech, but tremendous improvements especially with the mid-single-digit growth in hips and knees and continued innovation with our enabling technologies and specifically in VELYS.”
Over the last decade, minimal growth in knee replacement and substantial losses in spine offset the company’s slow but steady growth in hip replacement and trauma. The orthopedic market’s recovery since 2021 helped the company post more competitive growth rates in joint replacement, but trauma and spine remain well below market average.
The company did not provide 2025 guidance for its orthopedic business, but we expect dynamics similar to 2024. Growth is likely to be weighted toward the second half of the year due to tougher first-half competitors.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $941.8 | $903.0 | $38.8 | 4.3% |
| Knees | $398.4 | $386.6 | $11.8 | 3.1% |
| Hips | $418.5 | $397.8 | $20.7 | 5.2% |
| Extremities | $125.0 | $118.6 | $6.3 | 5.3% |
| Spine | $211.5 | $213.6 | ($2.1) | (1%) |
| Trauma | $679.9 | $660.4 | $19.5 | 3% |
| Sports Medicine | $183.8 | $178.0 | $5.8 | 3.3% |
| Orthobiologics | $99.2 | $96.4 | $2.8 | 2.9% |
| Enabling Technology | $19.8 | $18.5 | $1.3 | 7.1% |
| Other | $179.8 | $198.0 | ($18.2) | (9.2%) |
| Total | $2,315.8 | $2,267.9 | $48.0 | 2.1% |
| Segment | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $3,677.6 | $3,487.6 | $190.0 | 5.4% |
| Knees | $1,544.9 | $1,456.0 | $89.0 | 6.1% |
| Hips | $1,638.7 | $1,560.2 | $78.5 | 5% |
| Extremities | $494.0 | $471.5 | $22.6 | 4.8% |
| Spine | $934.1 | $944.0 | ($9.9) | (1%) |
| Trauma | $2,713.1 | $2,651.2 | $61.9 | 2.3% |
| Sports Medicine | $726.1 | $707.2 | $19.0 | 2.7% |
| Orthobiologics | $350.1 | $346.1 | $4.0 | 1.2% |
| Enabling Technology | $71.1 | $66.2 | $4.9 | 7.5% |
| Other | $685.8 | $739.4 | ($53.5) | (7.2%) |
| Total | $9,158.0 | $8,941.6 | $216.4 | 2.4% |
Orthopedic Sales by Geography
| Region | 4Q24 | 4Q23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,459.9 | $1,425.4 | $34.5 | 2.4% |
| OUS | $855.9 | $842.5 | $13.4 | 1.6% |
| EMEA | $392.0 | $383.3 | $8.7 | 2.3% |
| APAC | $280.7 | $278.0 | $2.7 | 1% |
| ROW | $183.2 | $181.1 | $2.0 | 1.1% |
| Total | $2,315.8 | $2,267.9 | $48.0 | 2.1% |
| Region | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $5,689.8 | $5,525.6 | $164.1 | 3% |
| OUS | $3,468.3 | $3,416.0 | $52.3 | 1.5% |
| EMEA | $1,635.1 | $1,582.1 | $53.0 | 3.3% |
| APAC | $1,140.2 | $1,151.7 | ($11.5) | (1%) |
| ROW | $693.0 | $682.2 | $10.8 | 1.6% |
| Total | $9,158.0 | $8,941.6 | $216.4 | 2.4% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $22,520.0 | |
| Cost of Sales | $7,128.0 | 31.7% |
| Selling and Admin | $6,453.0 | 28.7% |
| R & D | $5,298.0 | 23.5% |
| Other | $210.0 | 0.9% |
| Net Earnings | $3,431.0 | 15.2% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
